Candida auris is an emerging multidrug-resistant fungal pathogen posing a major global health threat. In this study, we employed a targeted drug-repurposing strategy to identify novel indications for existing FDA-approved compounds against C. auris, leading to the identification of Tavaborole as a potent fungistatic agent. Tavaborole displayed robust activity across all five tested clades of C. auris, as well as against Candida albicans and Candida glabrata. To investigate drug resistance mechan